Skip to search formSkip to main contentSkip to account menu

TAS 103

Known as: 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride, TAS-103 
A quinoline derivative that inhibits both topoisomerase I and II, causing a cytotoxic effect in cancer cells. (NCI)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Obstructive sleep apnea (OSA) patients present increased cardiovascular morbidity and mortality. Oxidative stress is involved in… 
2008
2008
In this paper, we show the physical limitations of semiconductor optical amplifier (SOA)-based switching nodes for optical burst… 
2007
2007
TAS-103, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno-[2,1-c]quinolin-7-one dihydrochloride, is a dual topoisomerases I… 
2005
2005
Drug-induced modifications of transcription factors play important roles in both apoptosis and survival signaling. The data… 
2001
2001
PURPOSE TAS-103 is an inhibitor of both topoisomerase I and II enzymes with broad antitumor activity. It is metabolized to TAS… 
Highly Cited
1999
Highly Cited
1999
TAS-103 is a novel anticancer drug that kills cells by increasing levels of DNA cleavage mediated by topoisomerase II. While most… 
1999
1999
[formula: see text] Hetero Diels-Alder reactions of (trialkylsilyl)vinylketenes (TAS-vinylketenes) with carbonyl and imino… 
1999
1999
To monitor cellular response to single doses of radiation (RT) and/or local tumor hyperthermia (LTH) proliferation kinetics were… 
Highly Cited
1960
Highly Cited
1960
Summary 1.A significant in vitro fibrinolytic activity could be obtained in plasma of rats given human fibrinolysin intravenously… 
1953
1953
Summary Local roentgen irradiation of spontaneous mammary carcinomas in DBA mice with doses of 1,000–2,000 r considerably…